Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

931632

registered interest
date	26/06/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Liothyronine
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what action they propose to ensure that the Brighton and Sussex University Hospitals NHS Trust withdraws its policy of no longer making Liothyronine (T3) available to NHS patients, contrary to advice issued by NHS England which sets out the circumstances under which Liothyronine (T3) can be prescribed to new patients and continued for existing patients.
tabling member printed	Lord Hunt of Kings Heath
uin	HL8980
answer	answer is ministerial correction date of answer 10/07/2018 answer text <p>The national guidelines advise clinical commissioning groups (CCGs) that local decisions should be made regarding arrangements for the on-going prescribing of liothyronine, taking into account the local needs of the population. While CCGs are expected to have regard to national guidance, they are entitled to develop their own local approaches to its implementation. During a debate on 20 June on the Branded Health Service Medicines (Costs) Regulations, I committed to pursuing further with NHS England ways in which they can clarify the guidelines on the prescribing of liothyronine to CCGs, including looking at whether greater clarity on the criteria for appropriate patient usage is merited.</p><p>The prescribing of Liothyronine (T3) was considered by the Sussex and East Surrey Sustainability and Transformation Partnership (STP) clinical board, which covers Brighton and Sussex University Hospitals, and High Weald, Lewes and Havens CCG, following engagement with primary care clinicians and endocrinologists. Based on the evidence presented, the decision not to routinely prescribe Liothyronine (T3) was supported across the STP region. It was, however, recognised that there would be some exceptions to this and that the use of the individual funding request triage process would be an appropriate mechanism to consider these.</p><p><strong> </strong></p> answering member printed Lord O'Shaughnessy grouped question UIN HL8981 HL8982 HL8983 question first answered 10/07/2018 15:41:18 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

931634

registered interest
date	26/06/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Liothyronine
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what assessment they have made of the Brighton and Sussex University Hospitals NHS Trust mistakenly stating that the only option for patients wishing to continue Liothyronine (T3) therapy is through the private sector, contrary to advice issued by NHS England which sets out the circumstances under which Liothyronine (T3) can be prescribed to new patients and continued for existing patients.
tabling member printed	Lord Hunt of Kings Heath
uin	HL8982
answer	answer is ministerial correction date of answer 10/07/2018 answer text <p>The national guidelines advise clinical commissioning groups (CCGs) that local decisions should be made regarding arrangements for the on-going prescribing of liothyronine, taking into account the local needs of the population. While CCGs are expected to have regard to national guidance, they are entitled to develop their own local approaches to its implementation. During a debate on 20 June on the Branded Health Service Medicines (Costs) Regulations, I committed to pursuing further with NHS England ways in which they can clarify the guidelines on the prescribing of liothyronine to CCGs, including looking at whether greater clarity on the criteria for appropriate patient usage is merited.</p><p>The prescribing of Liothyronine (T3) was considered by the Sussex and East Surrey Sustainability and Transformation Partnership (STP) clinical board, which covers Brighton and Sussex University Hospitals, and High Weald, Lewes and Havens CCG, following engagement with primary care clinicians and endocrinologists. Based on the evidence presented, the decision not to routinely prescribe Liothyronine (T3) was supported across the STP region. It was, however, recognised that there would be some exceptions to this and that the use of the individual funding request triage process would be an appropriate mechanism to consider these.</p><p><strong> </strong></p> answering member printed Lord O'Shaughnessy grouped question UIN HL8980 HL8981 HL8983 question first answered 10/07/2018 15:41:18 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

930912

registered interest
date	25/06/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Prescription Drugs: Misuse
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government whether they will ensure the timely publication of the agenda, papers and minutes of the Public Health England Expert Group on Prescribed Drug Dependence.
tabling member printed	Lord Hunt of Kings Heath
uin	HL8912
answer	answer is ministerial correction date of answer 09/07/2018 answer text <p>Public Health England (PHE) has been commissioned to undertake a public health evidence review of available data and published evidence on the problems associated with dependence, and the short term discontinuation or longer term withdrawal symptoms, associated with prescribed medicines.</p><p> </p><p>PHE is aware of the importance and relevance of the experience of patients in understanding the issues. The review will include a call for papers which specifically identifies published accounts of the patients’ experiences, and this material will be specifically and deliberately focused on in the review. This process is distinct from a public inquiry, which would include individual testimony.</p><p> </p><p>PHE is committed to publishing the agenda, papers and minutes of meetings of the expert reference group and the first set of these documents will be available during July 2018.</p> answering member printed Lord O'Shaughnessy grouped question UIN HL8913 question first answered 09/07/2018 14:17:45 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

930913

registered interest
date	25/06/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Prescription Drugs: Misuse
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government whether the Public Health England Expert Group on Prescribed Drug Dependence will accept as evidence the individual testimonies of patients.
tabling member printed	Lord Hunt of Kings Heath
uin	HL8913
answer	answer is ministerial correction date of answer 09/07/2018 answer text <p>Public Health England (PHE) has been commissioned to undertake a public health evidence review of available data and published evidence on the problems associated with dependence, and the short term discontinuation or longer term withdrawal symptoms, associated with prescribed medicines.</p><p> </p><p>PHE is aware of the importance and relevance of the experience of patients in understanding the issues. The review will include a call for papers which specifically identifies published accounts of the patients’ experiences, and this material will be specifically and deliberately focused on in the review. This process is distinct from a public inquiry, which would include individual testimony.</p><p> </p><p>PHE is committed to publishing the agenda, papers and minutes of meetings of the expert reference group and the first set of these documents will be available during July 2018.</p> answering member printed Lord O'Shaughnessy grouped question UIN HL8912 question first answered 09/07/2018 14:17:45 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

930914

registered interest
date	25/06/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Drugs: Misuse
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what assessment they have made of the extent to which the commissioning guidance for the NHS and local government on how to respond to the needs of people who are addicted to prescription and over the counter medicines, published by Public Health England in June 2013, has been implemented.
tabling member printed	Lord Hunt of Kings Heath
uin	HL8914
answer	answer is ministerial correction date of answer 09/07/2018 answer text <p>No assessment has been made of the extent to which the commissioning guidance has been implemented. Responding to the needs of people who are addicted to prescription and over the counter medicines is the responsibility of local authorities and the National Health Service in each area. Local authority and clinical commissioning group commissioners should work together to ensure that there are appropriate services and interventions available to meet the needs of their local populations.</p><p>Public Health England supports local commissioners to better understand and address local need, by publishing guidance and supplying information about people in touch with specialist substance misuse services who are being treated for addiction to medicines.</p><p>People who have developed problems with prescription and over the counter medicines should seek help from their general practitioner (GP) in the first instance. Specialist advice for GPs and support for patients with complex and severe problems is available from substance misuse services in each local authority across the country.</p> answering member printed Lord O'Shaughnessy grouped question UIN HL8915 question first answered 09/07/2018 14:18:52 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

930915

registered interest
date	25/06/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Drugs: Misuse
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what assessment they have made of the extent to which support is available in every area for people with a dependency on prescription or over the counter medicines as set out in the guidance published by Public Health England in June 2013.
tabling member printed	Lord Hunt of Kings Heath
uin	HL8915
answer	answer is ministerial correction date of answer 09/07/2018 answer text <p>No assessment has been made of the extent to which the commissioning guidance has been implemented. Responding to the needs of people who are addicted to prescription and over the counter medicines is the responsibility of local authorities and the National Health Service in each area. Local authority and clinical commissioning group commissioners should work together to ensure that there are appropriate services and interventions available to meet the needs of their local populations.</p><p>Public Health England supports local commissioners to better understand and address local need, by publishing guidance and supplying information about people in touch with specialist substance misuse services who are being treated for addiction to medicines.</p><p>People who have developed problems with prescription and over the counter medicines should seek help from their general practitioner (GP) in the first instance. Specialist advice for GPs and support for patients with complex and severe problems is available from substance misuse services in each local authority across the country.</p> answering member printed Lord O'Shaughnessy grouped question UIN HL8914 question first answered 09/07/2018 14:18:52 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

928853

registered interest
date	21/06/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Regional Medicines Optimisation Committees
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government whether they will request that NHS England requires that Regional Medicines Optimisation Committees put into the public domain papers that are presented to those committees.
tabling member printed	Lord Hunt of Kings Heath
uin	HL8854
answer	answer is ministerial correction date of answer 04/07/2018 answer text <p>NHS England is committed to transparency of decision making. The Regional Medicines Optimisation Committees will seek to publish all advice and minutes they are able to. It may not always be possible, however, to publish papers that contain commercially sensitive information.</p> answering member printed Lord O'Shaughnessy question first answered 04/07/2018 15:10:52 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

928854

registered interest
date	21/06/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Regional Medicines Optimisation Committees
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government whether they will request that NHS England requires that Regional Medicines Optimisation Committees put into the public domain draft minutes of previous meetings of those committees within a fortnight of meetings taking place.
tabling member printed	Lord Hunt of Kings Heath
uin	HL8855
answer	answer is ministerial correction date of answer 04/07/2018 answer text <p>We do not plan to make such a request. NHS England’s Medicines Optimisation Oversight Group, the governance group for the committees, has agreed that minutes of the Regional Medicines Optimisation Committees should be in the public domain within four weeks of a meeting.</p> answering member printed Lord O'Shaughnessy question first answered 04/07/2018 15:11:35 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

928855

registered interest
date	21/06/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Regional Medicines Optimisation Committees
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government whether they will request that NHS England requires that Regional Medicines Optimisation Committees consult patient groups before issuing advice to the NHS.
tabling member printed	Lord Hunt of Kings Heath
uin	HL8856
answer	answer is ministerial correction date of answer 04/07/2018 answer text <p>NHS England has reaffirmed that relevant patient groups will be consulted before Regional Medicines Optimisation Committees issue any guidance and advice to the National Health Service.</p> answering member printed Lord O'Shaughnessy question first answered 04/07/2018 15:11:14 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

928856

registered interest
date	21/06/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Regional Medicines Optimisation Committees
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government how many (1) lay, (2) patient group, and (3) professional, members have been appointed to the Regional Medicines Optimisation Committee (South).
tabling member printed	Lord Hunt of Kings Heath
uin	HL8857
answer	answer is ministerial correction date of answer 04/07/2018 answer text <p>The South Regional Medicines Optimisation Committee has two lay members and 27 professional members. There are no patient group representatives on the standing membership. NHS England, however, would expect patient representatives to be consulted where there are issues relevant to their areas of expertise or where support to develop patient centred advice is required.</p> answering member printed Lord O'Shaughnessy question first answered 04/07/2018 15:10:29 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	2024 label Biography information for Lord Hunt of Kings Heath